{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T20:48:42Z","timestamp":1792702122806,"version":"4.5.0"},"reference-count":113,"publisher":"Bentham Science Publishers Ltd.","issue":"14","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CPB"],"published-print":{"date-parts":[[2024,10]]},"abstract":"<jats:sec>\n                    <jats:title>:<\/jats:title>\n                    <jats:p>Inflammatory bowel disease (IBD) is a life-threatening complex disease. It causes\nchronic intestinal inflammation in GIT. IBD significantly affects people\u2019s lifestyles and carries a\nhigh risk of colon cancer. IBD involves the rectum, ileum, and colon, with clinical manifestations\nof bloody stools, weight loss, diarrhea, and abdominal pain. The prevalence of inflammatory\ndisease is increasing dramatically worldwide. Over 16 million people are affected annually in\nIndia, with an economic burden of $6.8- $8.8 billion for treatment. Modern medicine can manage\nIBD as immunosuppressive agents, corticosteroids, tumor necrosis factor antagonists, integrin\nblockers, and amino-salicylates. However, these approaches are allied with limitations such\nas limited efficacy, drug resistance, undesired side effects, and overall cost, which cannot be\nignored. Hence, the herbal bioactives derived from various plant resources can be employed in\nmanaging IBD. Science Direct, PubMed, Google, and Scopus databases have been searched for\nconclusively relevant herbal plant-based anti-inflammatory agent compositions. Studies were\nscreened through analysis of previously published review articles. Eminent herbal bioactives,\nnamely curcumin, resveratrol, ellagic acid, silybin, catechin, kaempferol, icariin, glycyrrhizin\nacid, berberine, quercetin, rutin, and thymol are reported to be effective against IBD. Herbal\nleads are promising treatment options for IBD; they have been shown to display antiinflammatory\nand antioxidant properties by targeting enzymes and regulating the expressions of\nvarious inflammatory mediators. Natural products have been reported to have anti-inflammatory\nproperties in various clinical and preclinical studies, and some are available as herbal preparations.\nHerbal medicine would be promising in association with the implication of a novel drug\ndelivery system for managing IBD.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2174\/0113892010282432231222060355","type":"journal-article","created":{"date-parts":[[2024,2,4]],"date-time":"2024-02-04T05:48:07Z","timestamp":1707025687000},"page":"1835-1857","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Recent Insight into Herbal Bioactives-based Novel Approaches for\nChronic Intestinal Inflammatory Disorders Therapy"],"prefix":"10.2174","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9192-5265","authenticated-orcid":true,"given":"Ranjit K.","family":"Harwansh","sequence":"first","affiliation":[{"name":"Institute of Pharmaceutical Research, GLA University, Mathura, 281406, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6334-5768","authenticated-orcid":true,"given":"Sonia","family":"Chauhan","sequence":"additional","affiliation":[{"name":"Institute of Pharmaceutical Research, GLA University, Mathura, 281406, India"},{"name":"NIET Pharmacy Institute, Greater\nNoida, 201310, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8962-6821","authenticated-orcid":true,"given":"Rohitas","family":"Deshmukh","sequence":"additional","affiliation":[{"name":"Institute of Pharmaceutical Research, GLA University, Mathura, 281406, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rupa","family":"Mazumder","sequence":"additional","affiliation":[{"name":"NIET Pharmacy Institute, Greater\nNoida, 201310, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"1746","DOI":"10.1080\/10428194.2017.1397662","volume":"59","author":"Dasgupta Y.","year":"2018","unstructured":"Dasgupta Y.; Golovine K.; Nieborowska-Skorska M.; Luo L.; Matlawska-Wasowska K.; Mullighan C.G.; Skorski T.; Drugging DNA repair to target T-ALL cells. Leuk Lymphoma  2018,59(7),1746-1749","journal-title":"Leuk Lymphoma"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1007\/s12032-023-02020-x","volume":"40","author":"Deshmukh R.","year":"2023","unstructured":"Deshmukh R.; Prajapati M.; Harwansh R.K.; A review on emerging targeted therapies for the management of metastatic colorectal cancers. Med Oncol  2023,40(6),159","journal-title":"Med Oncol"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1016\/j.pop.2017.07.010","volume":"44","author":"Sairenji T.","year":"2017","unstructured":"Sairenji T.; Collins K.L.; Evans D.V.; An update on inflammatory bowel disease. Prim Care  2017,44(4),673-692","journal-title":"Prim Care"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1053\/j.gastro.2016.10.020","volume":"152","author":"Kaplan G.G.","year":"2017","unstructured":"Kaplan G.G.; Ng S.C.; Understanding and preventing the global increase of inflammatory bowel disease. Gastroenterology  2017,152(2),313-321.e2","journal-title":"Gastroenterology"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2019\/7247238","volume":"2019","author":"Guan Q.","year":"2019","unstructured":"Guan Q.; A comprehensive review and update on the pathogenesis of inflammatory bowel disease. J Immunol Res  2019,2019,1-16","journal-title":"J Immunol Res"},{"key":"ref=6","first-page":"956","volume":"13","author":"Deshmukh R.","year":"2020","unstructured":"Deshmukh R.; Kumari, S Inflammatory bowel disease: A snapshot of current knowledge. J Gastroenterol Hepatol  2020,13,956-962","journal-title":"J Gastroenterol Hepatol"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1038\/s41575-020-00360-x","volume":"18","author":"Kaplan G.G.","year":"2021","unstructured":"Kaplan G.G.; Windsor J.W.; The four epidemiological stages in the global evolution of inflammatory bowel disease. Nat Rev Gastroenterol Hepatol  2021,18(1),56-66","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"26","DOI":"10.5217\/ir.2018.16.1.26","volume":"16","author":"Lee S.H.","year":"2018","unstructured":"Lee S.H.; Kwon J.; Cho M.L.; Immunological pathogenesis of inflammatory bowel disease. Intest Res  2018,16(1),26-42","journal-title":"Intest Res"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1111\/jgh.14872","volume":"35","author":"Mak W.Y.","year":"2020","unstructured":"Mak W.Y.; Zhao M.; Ng S.C.; Burisch J.; The epidemiology of inflammatory bowel disease: East meets west. J Gastroenterol Hepatol  2020,35(3),380-389","journal-title":"J Gastroenterol Hepatol"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1053\/j.gastro.2020.05.011","volume":"159","author":"Lo C.H.","year":"2020","unstructured":"Lo C.H.; Lochhead P.; Khalili H.; Song M.; Tabung F.K.; Burke K.E.; Richter J.M.; Giovannucci E.L.; Chan A.T.; Ananthakrishnan A.N.; Dietary inflammatory potential and risk of crohn\u2019s disease and ulcerative colitis. Gastroenterology  2020,159(3),873-883.e1","journal-title":"Gastroenterology"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.3748\/wjg.v20.i5.1165","volume":"20","author":"Antoni L.","year":"2014","unstructured":"Antoni L.; Nuding S.; Wehkamp J.; Stange E.F.; Intestinal barrier in inflammatory bowel disease. World J Gastroenterol  2014,20(5),1165-1179","journal-title":"World J Gastroenterol"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1002\/ibd.21403","volume":"17","author":"Salim S.Y.","year":"2011","unstructured":"Salim S.Y.; S\u00f6derholm J.D.; Importance of disrupted intestinal barrier in inflammatory bowel diseases. Inflamm Bowel Dis  2011,17(1),362-381","journal-title":"Inflamm Bowel Dis"},{"key":"ref=13","doi-asserted-by":"crossref","first-page":"3997","DOI":"10.2174\/1381612823666170228123357","volume":"23","author":"Sgambato D.","year":"2017","unstructured":"Sgambato D.; Miranda A.; Ranaldo R.; Federico A.; Romano M.; The role of stress in inflammatory bowel diseases. Curr Pharm Des  2017,23(27),3997-4002","journal-title":"Curr Pharm Des"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1136\/gutjnl-2012-303956","volume":"62","author":"Uhlig H.H.","year":"2013","unstructured":"Uhlig H.H.; Monogenic diseases associated with intestinal inflammation: Implications for the understanding of inflammatory bowel disease. Gut  2013,62(12),1795-1805","journal-title":"Gut"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1007\/s10620-014-3350-9","volume":"60","author":"Ananthakrishnan A.N.","year":"2015","unstructured":"Ananthakrishnan A.N.; Environmental risk factors for inflammatory bowel diseases: A review. Dig Dis Sci  2015,60(2),290-298","journal-title":"Dig Dis Sci"},{"key":"ref=16","first-page":"367","volume":"9","author":"Ananthakrishnan A.N.","year":"2013","unstructured":"Ananthakrishnan A.N.; Environmental risk factors for inflammatory bowel disease. Gastroenterol Hepatol  2013,9(6),367-374","journal-title":"Gastroenterol Hepatol"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"193","DOI":"10.3390\/cells8020193","volume":"8","author":"Schoultz I.","year":"2019","unstructured":"Schoultz I.; Keita \u00c5.; Cellular and molecular therapeutic targets in inflammatory bowel disease\u2014focusing on intestinal barrier function. Cells  2019,8(2),193","journal-title":"Cells"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1053\/j.gastro.2019.04.016","volume":"157","author":"Piovani D.","year":"2019","unstructured":"Piovani D.; Danese S.; Peyrin-Biroulet L.; Nikolopoulos G.K.; Lytras T.; Bonovas S.; Environmental risk factors for inflammatory bowel diseases: An umbrella review of meta-analyses. Gastroenterology  2019,157(3),647-659.e4","journal-title":"Gastroenterology"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/S0140-6736(02)07284-7","volume":"359","author":"Shanahan F.","year":"2002","unstructured":"Shanahan F.; Crohn\u2019s disease. Lancet  2002,359(9300),62-69","journal-title":"Lancet"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1080\/17474124.2019.1574569","volume":"13","author":"Greuter T.","year":"2019","unstructured":"Greuter T.; Vavricka S.R.; Extraintestinal manifestations in inflammatory bowel disease - epidemiology, genetics, and pathogenesis. Expert Rev Gastroenterol Hepatol  2019,13(4),307-317","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1038\/ncpgasthep0528","volume":"3","author":"Sartor R.B.","year":"2006","unstructured":"Sartor R.B.; Mechanisms of Disease: Pathogenesis of Crohn\u2019s disease and ulcerative colitis. Nat Clin Pract Gastroenterol Hepatol  2006,3(7),390-407","journal-title":"Nat Clin Pract Gastroenterol Hepatol"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"S5","DOI":"10.1093\/ibd\/izz075","volume":"25","author":"Pizarro T.T.","year":"2019","unstructured":"Pizarro T.T.; Stappenbeck T.S.; Rieder F.; Rosen M.J.; Colombel J.F.; Donowitz M.; Towne J.; Mazmanian S.K.; Faith J.J.; Hodin R.A.; Garrett W.S.; Fichera A.; Poritz L.S.; Cortes C.J.; Shtraizent N.; Honig G.; Snapper S.B.; Hurtado-Lorenzo A.; Salzman N.H.; Chang E.B.; Challenges in IBD research: Preclinical human IBD mechanisms. Inflamm Bowel Dis  2019,25(S2),S5-S12","journal-title":"Inflamm Bowel Dis"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.3748\/wjg.v18.i15.1708","volume":"18","author":"Qin X.","year":"2012","unstructured":"Qin X.; Etiology of inflammatory bowel disease: A unified hypothesis. World J Gastroenterol  2012,18(15),1708-1722","journal-title":"World J Gastroenterol"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1080\/00365521.2018.1447597","volume":"53","author":"Ahluwalia B.","year":"2018","unstructured":"Ahluwalia B.; Moraes L.; Magnusson M.K.; \u00d6hman L.; Immunopathogenesis of inflammatory bowel disease and mechanisms of biological therapies. Scand J Gastroenterol  2018,53(4),379-389","journal-title":"Scand J Gastroenterol"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1038\/mi.2015.48","volume":"9","author":"Magnusson M.K.","year":"2016","unstructured":"Magnusson M.K.; Brynj\u00f3lfsson S.F.; Dige A.; Uronen-Hansson H.; B\u00f6rjesson L.G.; Bengtsson J.L.; Gudjonsson S.; \u00d6hman L.; Agnholt J.; Sj\u00f6vall H.; Agace W.W.; Wick M.J.; Macrophage and dendritic cell subsets in IBD: ALDH+ cells are reduced in colon tissue of patients with ulcerative colitis regardless of inflammation. Mucosal Immunol  2016,9(1),171-182","journal-title":"Mucosal Immunol"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1515\/jbcpp-2018-0036","volume":"30","author":"Tatiya-aphiradee N.","year":"2018","unstructured":"Tatiya-aphiradee N.; Chatuphonprasert W.; Jarukamjorn K.; Immune response and inflammatory pathway of ulcerative colitis. J Basic Clin Physiol Pharmacol  2018,30(1),1-10","journal-title":"J Basic Clin Physiol Pharmacol"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1038\/nature06005","volume":"448","author":"Xavier R.J.","year":"2007","unstructured":"Xavier R.J.; Podolsky D.K.; Unravelling the pathogenesis of inflammatory bowel disease. Nature  2007,448(7152),427-434","journal-title":"Nature"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1016\/S0923-2494(98)80152-1","volume":"148","author":"Powrie F.","year":"1997","unstructured":"Powrie F.; Mauze S.; Coffman R.L.; CD4+ T-cells in the regulation of inflammatory responses in the intestine. Res Immunol  1997,148(8-9),576-581","journal-title":"Res Immunol"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1111\/imr.12726","volume":"287","author":"Pazmandi J.","year":"2019","unstructured":"Pazmandi J.; Kalinichenko A.; Ardy R.C.; Boztug K.; Early\u2010onset inflammatory bowel disease as a model disease to identify key regulators of immune homeostasis mechanisms. Immunol Rev  2019,287(1),162-185","journal-title":"Immunol Rev"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1007\/s10620-020-06090-z","volume":"65","author":"Oka A.","year":"2020","unstructured":"Oka A.; Sartor R.B.; Microbial-based and microbial-targeted therapies for inflammatory bowel diseases. Dig Dis Sci  2020,65(3),757-788","journal-title":"Dig Dis Sci"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"2574","DOI":"10.1111\/j.1462-2920.2009.01982.x","volume":"11","author":"Tap J.","year":"2009","unstructured":"Tap J.; Mondot S.; Levenez F.; Pelletier E.; Caron C.; Furet J.P.; Ugarte E.; Mu\u00f1oz-Tamayo R.; Paslier D.L.E.; Nalin R.; Dore J.; Leclerc M.; Towards the human intestinal microbiota phylogenetic core. Environ Microbiol  2009,11(10),2574-2584","journal-title":"Environ Microbiol"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1093\/ibd\/izy386","volume":"25","author":"Schmitz J.M.","year":"2019","unstructured":"Schmitz J.M.; Tonkonogy S.L.; Dogan B.; Leblond A.; Whitehead K.J.; Kim S.C.; Simpson K.W.; Sartor R.B.; Murine adherent and invasive E. coli induces chronic inflammation and immune responses in the small and large intestines of monoassociated IL-10-\/- mice independent of long polar fimbriae adhesin A. Inflamm Bowel Dis  2019,25(5),875-885","journal-title":"Inflamm Bowel Dis"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1016\/S0002-9270(02)03970-9","volume":"97","author":"Allez M.","year":"2002","unstructured":"Allez M.; Lemann M.; Bonnet J.; Cattan P.; Jian R.; Modigliani R.; Long term outcome of patients with active Crohn\u2019s disease exhibiting extensive and deep ulcerations at colonoscopy. Am J Gastroenterol  2002,97(4),947-953","journal-title":"Am J Gastroenterol"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1007\/s00535-020-01678-8","volume":"55","author":"Takenaka K.","year":"2020","unstructured":"Takenaka K.; Kitazume Y.; Fujii T.; Tsuchiya K.; Watanabe M.; Ohtsuka K.; Objective evaluation for treat to target in Crohn\u2019s disease. J Gastroenterol  2020,55(6),579-587","journal-title":"J Gastroenterol"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1016\/S0140-6736(14)61908-5","volume":"385","author":"De Cruz P.","year":"2015","unstructured":"De Cruz P.; Kamm M.A.; Hamilton A.L.; Ritchie K.J.; Krejany E.O.; Gorelik A.; Liew D.; Prideaux L.; Lawrance I.C.; Andrews J.M.; Bampton P.A.; Gibson P.R.; Sparrow M.; Leong R.W.; Florin T.H.; Gearry R.B.; Radford-Smith G.; Macrae F.A.; Debinski H.; Selby W.; Kronborg I.; Johnston M.J.; Woods R.; Elliott P.R.; Bell S.J.; Brown S.J.; Connell W.R.; Desmond P.V.; Crohn\u2019s disease management after intestinal resection: a randomised trial. Lancet  2015,385(9976),1406-1417","journal-title":"Lancet"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1111\/ijcp.12187","volume":"67","author":"Chatu S.","year":"2013","unstructured":"Chatu S.; Poullis A.; Holmes R.; Greenhalgh R.; Pollok R.C.G.; Temporal trends in imaging and associated radiation exposure in inflammatory bowel disease. Int J Clin Pract  2013,67(10),1057-1065","journal-title":"Int J Clin Pract"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1148\/rg.263055162","volume":"26","author":"Paulsen S.R.","year":"2006","unstructured":"Paulsen S.R.; Huprich J.E.; Fletcher J.G.; Booya F.; Young B.M.; Fidler J.L.; Johnson C.D.; Barlow J.M.; Earnest F.; IV CT enterography as a diagnostic tool in evaluating small bowel disorders: review of clinical experience with over 700 cases. Radiographics  2006,26(3),641-657","journal-title":"Radiographics"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"28","DOI":"10.4253\/wjge.v4.i2.28","volume":"4","author":"Manno M.","year":"2012","unstructured":"Manno M.; Barbera C.; Bertani H.; Manta R.; Mirante V.G.; Dabizzi E.; Caruso A.; Pigo F.; Olivetti G.; Conigliaro R.; Single balloon enteroscopy: Technical aspects and clinical applications. World J Gastrointest Endosc  2012,4(2),28-32","journal-title":"World J Gastrointest Endosc"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"14479","DOI":"10.3748\/wjg.v20.i39.14479","volume":"20","author":"Fan R.","year":"2014","unstructured":"Fan R.; Zhong J.; Wang Z.T.; Li S.Y.; Zhou J.; Tang Y.H.; Evaluation of \u201ctop-down\u201d treatment of early Crohn\u2019s disease by double balloon enteroscopy. World J Gastroenterol  2014,20(39),14479-14487","journal-title":"World J Gastroenterol"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1093\/ecco-jcc\/jjx159","volume":"12","author":"Hirai F.","year":"2018","unstructured":"Hirai F.; Andoh A.; Ueno F.; Watanabe K.; Ohmiya N.; Nakase H.; Kato S.; Esaki M.; Endo Y.; Yamamoto H.; Matsui T.; Iida M.; Hibi T.; Watanabe M.; Suzuki Y.; Matsumoto T.; Efficacy of endoscopic balloon dilation for small bowel strictures in patients with Crohn\u2019s Disease: A nationwide, multi-centre, open-label, prospective cohort study. J Crohn\u2019s Colitis  2018,12(4),394-401","journal-title":"J Crohn\u2019s Colitis"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"8999","DOI":"10.3748\/wjg.v22.i40.8999","volume":"22","author":"Arulanandan A.","year":"2016","unstructured":"Arulanandan A.; Dulai P.S.; Singh S.; Sandborn W.J.; Kalmaz D.; Systematic review: Safety of balloon assisted enteroscopy in Crohn\u2019s disease. World J Gastroenterol  2016,22(40),8999-9011","journal-title":"World J Gastroenterol"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1093\/ecco-jcc\/jjx116","volume":"12","author":"Orlando S.","year":"2018","unstructured":"Orlando S.; Fraquelli M.; Coletta M.; Branchi F.; Magarotto A.; Conti C.B.; Mazza S.; Conte D.; Basilisco G.; Caprioli F.; Ultrasound elasticity imaging predicts therapeutic outcomes of patients with crohn\u2019s disease treated with anti-tumour necrosis factor antibodies. J Crohn\u2019s Colitis  2018,12(1),63-70","journal-title":"J Crohn\u2019s Colitis"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1007\/s00247-015-3517-3","volume":"46","author":"Dillman J.R.","year":"2016","unstructured":"Dillman J.R.; Smith E.A.; Sanchez R.; DiPietro M.A.; Fazeli Dehkordy S.; Adler J.; DeMatos-Maillard V.; Khalatbari S.; Davenport M.S.; Prospective cohort study of ultrasound-ultrasound and ultrasound-MR enterography agreement in the evaluation of pediatric small bowel Crohn disease. Pediatr Radiol  2016,46(4),490-497","journal-title":"Pediatr Radiol"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.1056\/NEJMc1612455","volume":"376","author":"Knieling F.","year":"2017","unstructured":"Knieling F.; Neufert C.; Hartmann A.; Claussen J.; Urich A.; Egger C.; Vetter M.; Fischer S.; Pfeifer L.; Hagel A.; Kielisch C.; G\u00f6rtz R.S.; Wildner D.; Engel M.; R\u00f6ther J.; Uter W.; Siebler J.; Atreya R.; Rascher W.; Strobel D.; Neurath M.F.; Waldner M.J.; Multispectral optoacoustic tomography for assessment of crohn\u2019s disease activity. N Engl J Med  2017,376(13),1292-1294","journal-title":"N Engl J Med"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1093\/ibd\/izy091","volume":"24","author":"Calabrese E.","year":"2018","unstructured":"Calabrese E.; Kucharzik T.; Maaser C.; Maconi G.; Strobel D.; Wilson S.R.; Zorzi F.; Novak K.L.; Bruining D.H.; Iacucci M.; Watanabe M.; Lolli E.; Chiaramonte C.; Hanauer S.B.; Panaccione R.; Pallone F.; Ghosh S.; Monteleone G.; Real-time interobserver agreement in bowel ultrasonography for diagnostic assessment in patients with crohn\u2019s disease: An international multicenter study. Inflamm Bowel Dis  2018,24(9),2001-2006","journal-title":"Inflamm Bowel Dis"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1016\/j.jsps.2014.10.001","volume":"24","author":"Nidhi R.M.","year":"2016","unstructured":"Nidhi R.M.; Rashid M.; Kaur V.; Hallan S.S.; Sharma S.; Mishra N.; Microparticles as controlled drug delivery carrier for the treatment of ulcerative colitis: A brief review. Saudi Pharm J  2016,24(4),458-472","journal-title":"Saudi Pharm J"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"101495","DOI":"10.1016\/j.jddst.2019.101495","volume":"55","author":"Deshmukh R.","year":"2020","unstructured":"Deshmukh R.; Harwansh R.K.; Paul S.D.; Shukla R.; Controlled release of sulfasalazine loaded amidated pectin microparticles through Eudragit S 100 coated capsule for management of inflammatory bowel disease. J Drug Deliv Sci Technol  2020,55,101495","journal-title":"J Drug Deliv Sci Technol"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"3","DOI":"10.4103\/1319-3767.91726","volume":"18","author":"Ju L.Z.","year":"2012","unstructured":"Ju L.Z.; Ke F.; Yadav P.K.; Herbal medicine in the treatment of ulcerative colitis. Saudi J Gastroenterol  2012,18(1),3-10","journal-title":"Saudi J Gastroenterol"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"161","DOI":"10.2174\/1386207321666180213093449","volume":"21","author":"Suroowan S.","year":"2018","unstructured":"Suroowan S.; Mahomoodally F.; Herbal products for common auto-inflammatory disorders - novel approaches. Comb Chem High Throughput Screen  2018,21(3),161-174","journal-title":"Comb Chem High Throughput Screen"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/j.intimp.2014.09.026","volume":"23","author":"Wu X.","year":"2014","unstructured":"Wu X.; Yang Y.; Dou Y.; Ye J.; Bian D.; Wei Z.; Tong B.; Kong L.; Xia Y.; Dai Y.; Arctigenin but not arctiin acts as the major effective constituent of Arctium lappa L. fruit for attenuating colonic inflammatory response induced by dextran sulfate sodium in mice. Int Immunopharmacol  2014,23(2),505-515","journal-title":"Int Immunopharmacol"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"100216","DOI":"10.18632\/oncotarget.22145","volume":"8","author":"Ai X.Y.","year":"2017","unstructured":"Ai X.Y.; Qin Y.; Liu H.J.; Cui Z.H.; Li M.; Yang J.H.; Zhong W.L.; Liu Y.R.; Chen S.; Sun T.; Zhou H.G.; Yang C.; Apigenin inhibits colonic inflammation and tumorigenesis by suppressing STAT3-NF-\u03baB signaling. Oncotarget  2017,8(59),100216-100226","journal-title":"Oncotarget"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"877","DOI":"10.3748\/wjg.v24.i8.877","volume":"24","author":"Hoensch H.P.","year":"2018","unstructured":"Hoensch H.P.; Weigmann B.; Regulation of the intestinal immune system by flavonoids and its utility in chronic inflammatory bowel disease. World J Gastroenterol  2018,24(8),877-881","journal-title":"World J Gastroenterol"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.jnutbio.2015.12.002","volume":"30","author":"M\u00e1rquez-Flores Y.K.","year":"2016","unstructured":"M\u00e1rquez-Flores Y.K.; Villegas I.; C\u00e1rdeno A.; Rosillo M.\u00c1.; Alarc\u00f3n-de-la-Lastra C.; Apigenin supplementation protects the development of dextran sulfate sodium-induced murine experimental colitis by inhibiting canonical and non-canonical inflammasome signaling pathways. J Nutr Biochem  2016,30,143-152","journal-title":"J Nutr Biochem"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1038\/s41401-019-0335-4","volume":"41","author":"Liu Q.","year":"2020","unstructured":"Liu Q.; Zuo R.; Wang K.; Nong F.; Fu Y.; Huang S.; Pan Z.; Zhang Y.; Luo X.; Deng X.; Zhang X.; Zhou L.; Chen Y.; Oroxindin inhibits macrophage NLRP3 inflammasome activation in DSS-induced ulcerative colitis in mice via suppressing TXNIP-dependent NF-\u03baB pathway. Acta Pharmacol Sin  2020,41(6),771-781","journal-title":"Acta Pharmacol Sin"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1038\/s41401-021-00781-7","volume":"43","author":"Li Y.","year":"2022","unstructured":"Li Y.; Wang X.; Su Y.; Wang Q.; Huang S.; Pan Z.; Chen Y.; Liang J.; Zhang M.; Xie X.; Wu Z.; Chen J.; Zhou L.; Luo X.; Baicalein ameliorates ulcerative colitis by improving intestinal epithelial barrier via AhR\/IL-22 pathway in ILC3s. Acta Pharmacol Sin  2022,43(6),1495-1507","journal-title":"Acta Pharmacol Sin"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"16374","DOI":"10.1038\/s41598-017-12562-6","volume":"7","author":"Luo X.","year":"2017","unstructured":"Luo X.; Yu Z.; Deng C.; Zhang J.; Ren G.; Sun A.; Mani S.; Wang Z.; Dou W.; Baicalein ameliorates TNBS-induced colitis by suppressing TLR4\/MyD88 signaling cascade and NLRP3 inflammasome activation in mice. Sci Rep  2017,7(1),16374","journal-title":"Sci Rep"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/j.intimp.2018.09.008","volume":"64","author":"Zhou J.","year":"2018","unstructured":"Zhou J.; Wang T.; Dou Y.; Huang Y.; Qu C.; Gao J.; Huang Z.; Xie Y.; Huang P.; Lin Z.; Su Z.; Brusatol ameliorates 2, 4, 6-trinitrobenzenesulfonic acid-induced experimental colitis in rats: Involvement of NF-\u03baB pathway and NLRP3 inflammasome. Int Immunopharmacol  2018,64,264-274","journal-title":"Int Immunopharmacol"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.molimm.2018.10.015","volume":"105","author":"Mai C.T.","year":"2019","unstructured":"Mai C.T.; Wu M.M.; Wang C.L.; Su Z.R.; Cheng Y.Y.; Zhang X.J.; Palmatine attenuated dextran sulfate sodium (DSS)-induced colitis via promoting mitophagy-mediated NLRP3 inflammasome inactivation. Mol Immunol  2019,105,76-85","journal-title":"Mol Immunol"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.phrs.2018.09.010","volume":"137","author":"Zhang X.J.","year":"2018","unstructured":"Zhang X.J.; Yuan Z.W.; Qu C.; Yu X.T.; Huang T.; Chen P.V.; Su Z.R.; Dou Y.X.; Wu J.Z.; Zeng H.F.; Xie Y.; Chen J.N.; Palmatine ameliorated murine colitis by suppressing tryptophan metabolism and regulating gut microbiota. Pharmacol Res  2018,137,34-46","journal-title":"Pharmacol Res"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"2026","DOI":"10.18632\/oncotarget.27592","volume":"11","author":"Chaparala A.","year":"2020","unstructured":"Chaparala A.; Poudyal D.; Tashkandi H.; Witalison E.E.; Chumanevich A.A.; Hofseth J.L.; Nguyen I.; Hardy O.; Pittman D.L.; Wyatt M.D.; Windust A.; Murphy E.A.; Nagarkatti M.; Nagarkatti P.; Hofseth L.J.; Panaxynol, a bioactive component of American ginseng, targets macrophages and suppresses colitis in mice. Oncotarget  2020,11(22),2026-2036","journal-title":"Oncotarget"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.lfs.2016.01.001","volume":"146","author":"Lee C.","year":"2016","unstructured":"Lee C.; Lee J.W.; Seo J.Y.; Hwang S.W.; Im, J.P.; Kim, J.S. Lupeol inhibits LPS-induced NF-kappa B signaling in intestinal epithelial cells and macrophages, and attenuates acute and chronic murine colitis. Life Sci  2016,146,100-108","journal-title":"Life Sci"},{"key":"ref=62","first-page":"S83","volume":"23","author":"Socca E.A.","year":"2017","unstructured":"Socca E.A.; Dunder R.; de Almeida A.C.; Manzo L.; de-Faria F.; Maia G.L.; Barboza-Filho J.M.; Regina S-B.; Luiz-Ferreira A.; P-255 therapy with lupeol, a natural pentacyclic triterpenoid, attenuates intestinal inflammation in rat. Inflamm Bowel Dis  2017,23,S83-S84","journal-title":"Inflamm Bowel Dis"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1016\/j.jep.2013.09.030","volume":"150","author":"Mar\u00edn M.","year":"2013","unstructured":"Mar\u00edn M.; Giner R.; R\u00edos J.L.; Carmen Recio M.; Intestinal anti-inflammatory activity of ellagic acid in the acute and chronic dextrane sulfate sodium models of mice colitis. J Ethnopharmacol  2013,150(3),925-934","journal-title":"J Ethnopharmacol"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"2037","DOI":"10.3390\/ijms19072037","volume":"19","author":"Ran X.","year":"2018","unstructured":"Ran X.; Li Y.; Chen G.; Fu S.; He D.; Huang B.; Wei L.; Lin Y.; Guo Y.; Hu G.; Farrerol ameliorates TNBS-induced colonic inflammation by inhibiting ERK1\/2, JNK1\/2, and NF-\u03baB signaling pathway. Int J Mol Sci  2018,19(7),2037","journal-title":"Int J Mol Sci"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1016\/j.ejphar.2014.06.013","volume":"740","author":"Jeong J.J.","year":"2014","unstructured":"Jeong J.J.; Jang S.E.; Hyam S.R.; Han M.J.; Kim D.H.; Mangiferin ameliorates colitis by inhibiting IRAK1 phosphorylation in NF-\u03baB and MAPK pathways. Eur J Pharmacol  2014,740,652-661","journal-title":"Eur J Pharmacol"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.cbi.2016.04.033","volume":"253","author":"Somani S.","year":"2016","unstructured":"Somani S.; Zambad S.; Modi K.; Mangiferin attenuates DSS colitis in mice: Molecular docking and in vivo approach. Chem Biol Interact  2016,253,18-26","journal-title":"Chem Biol Interact"},{"key":"ref=67","first-page":"538","volume":"9","author":"Tahmasebi P.","year":"2019","unstructured":"Tahmasebi P.; Froushani S.M.; Ahangaran N.; Thymol has beneficial effects on the experimental model of ulcerative colitis. Avicenna J Phytomed  2019,9(6),538-550","journal-title":"Avicenna J Phytomed"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1007\/s10787-019-00583-8","volume":"27","author":"Chamanara M.","year":"2019","unstructured":"Chamanara M.; Abdollahi A.; Rezayat S.M.; Ghazi-Khansari M.; Dehpour A.; Nassireslami E.; Rashidian A.; Thymol reduces acetic acid-induced inflammatory response through inhibition of NF-kB signaling pathway in rat colon tissue. Inflammopharmacology  2019,27(6),1275-1283","journal-title":"Inflammopharmacology"},{"key":"ref=69","first-page":"447","volume":"35","author":"Liu X.","year":"2019","unstructured":"Liu X.; Wu Y.L.; Liu K.L.; Cui X.L.; Du X.X.; Zhang W.Q.; Effects of resveratrol on ulcerative colitis in mice and its mechanism. Chung Kuo Ying Yung Sheng Li Hsueh Tsa Chih  2019,35(5),447-453","journal-title":"Chung Kuo Ying Yung Sheng Li Hsueh Tsa Chih"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1248\/bpb.b19-00786","volume":"43","author":"Wang J.","year":"2020","unstructured":"Wang J.; Zhang Z.; Fang A.; Wu K.; Chen X.; Wang G.; Mao F.; Resveratrol attenuates inflammatory bowel disease in mice by regulating SUMO1. Biol Pharm Bull  2020,43(3),450-457","journal-title":"Biol Pharm Bull"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"G85","DOI":"10.1152\/ajpgi.00275.2011","volume":"302","author":"Midura-Kiela M.T.","year":"2012","unstructured":"Midura-Kiela M.T.; Radhakrishnan V.M.; Larmonier C.B.; Laubitz D.; Ghishan F.K.; Kiela P.R.; Curcumin inhibits interferon-\u03b3 signaling in colonic epithelial cells. Am J Physiol Gastrointest Liver Physiol  2012,302(1),G85-G96","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"583","DOI":"10.4155\/fmc-2023-0048","volume":"15","author":"Bhat A.A.","year":"2023","unstructured":"Bhat A.A.; Thapa R.; Goyal A.; Subramaniyan V.; Kumar D.; Gupta S.; Singh S.K.; Dua K.; Gupta G.; Curcumin-based nanoformulations as an emerging therapeutic strategy for inflammatory lung diseases. Future Med Chem  2023,15(7),583-586","journal-title":"Future Med Chem"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"2483","DOI":"10.1097\/MIB.0000000000000522","volume":"21","author":"McFadden R.M.T.","year":"2015","unstructured":"McFadden R.M.T.; Larmonier C.B.; Shehab K.W.; Midura-Kiela M.; Ramalingam R.; Harrison C.A.; Besselsen D.G.; Chase J.H.; Caporaso J.G.; Jobin C.; Ghishan F.K.; Kiela P.R.; The role of curcumin in modulating colonic microbiota during colitis and colon cancer prevention. Inflamm Bowel Dis  2015,21(11),2483-2494","journal-title":"Inflamm Bowel Dis"},{"key":"ref=74","first-page":"23","volume":"23","author":"Wei C.","year":"2021","unstructured":"Wei C.; Wang J.Y.; Xiong F.; Wu B.H.; Luo M.H.; Yu Z.C.; Liu T.T.; Li D.F.; Tang Q.; Li Y.X.; Zhang D.G.; Xu Z.L.; Jin H.T.; Wang L.S.; Yao J.; Curcumin ameliorates DSS induced colitis in mice by regulating the Treg\/Th17 signaling pathway. Mol Med Rep  2021,23(1),23","journal-title":"Mol Med Rep"},{"key":"ref=75","first-page":"4210","volume":"10","author":"Bastaki S.M.","year":"2018","unstructured":"Bastaki S.M.; Adeghate E.; Amir N.; Ojha S.; Oz M.; Menthol inhibits oxidative stress and inflammation in acetic acid-induced colitis in rat colonic mucosa. Am J Transl Res  2018,10(12),4210-4222","journal-title":"Am J Transl Res"},{"key":"ref=76","first-page":"9296","volume":"13","author":"Lu Q.","year":"2021","unstructured":"Lu Q.; Wu X.; Han W.; Zhang W.; Wang Y.; Kong D.; Fan Z.; Effect of Glycyrrhiza uralensis against ulcerative colitis through regulating the signaling pathway of FXR\/P-gp. Am J Transl Res  2021,13(8),9296-9305","journal-title":"Am J Transl Res"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2021\/6679316","volume":"2021","author":"Sheng Q.","year":"2021","unstructured":"Sheng Q.; Li F.; Chen G.; Li J.; Li J.; Wang Y.; Lu Y.; Li Q.; Li M.; Chai K.; Ursolic acid regulates intestinal microbiota and inflammatory cell infiltration to prevent ulcerative colitis. J Immunol Res  2021,2021,1-16","journal-title":"J Immunol Res"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.biopha.2008.02.002","volume":"62","author":"Ran Z.H.","year":"2008","unstructured":"Ran Z.H.; Chen C.; Xiao S.D.; Epigallocatechin-3-gallate ameliorates rats colitis induced by acetic acid. Biomed Pharmacother  2008,62(3),189-196","journal-title":"Biomed Pharmacother"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/j.ejphar.2007.10.053","volume":"579","author":"Abboud P.A.","year":"2008","unstructured":"Abboud P.A.; Hake P.W.; Burroughs T.J.; Odoms K.; O\u2019Connor M.; Mangeshkar P.; Wong H.R.; Zingarelli B.; Therapeutic effect of epigallocatechin-3-gallate in a mouse model of colitis. Eur J Pharmacol  2008,579(1-3),411-417","journal-title":"Eur J Pharmacol"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1080\/10520295.2018.1530454","volume":"94","author":"Polat F.R.","year":"2019","unstructured":"Polat F.R.; Karabo\u011fa \u0130.; Immunohistochemical examination of anti-inflammatory and anti-apoptotic effects of hesperetin on trinitrobenzene sulfonic acid induced colitis in rats. Biotech Histochem  2019,94(3),151-158","journal-title":"Biotech Histochem"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"6490","DOI":"10.1080\/21655979.2022.2031676","volume":"13","author":"Chen A.","year":"2022","unstructured":"Chen A.; Fang D.; Ren Y.; Wang Z.; Matrine protects colon mucosal epithelial cells against inflammation and apoptosis via the Janus kinase 2\/signal transducer and activator of transcription 3 pathway. Bioengineered  2022,13(3),6490-6499","journal-title":"Bioengineered"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"325","DOI":"10.2174\/1566524021666210315125330","volume":"22","author":"Goyal A.","year":"2022","unstructured":"Goyal A.; Agrawal N.; Quercetin: A potential candidate for the treatment of arthritis. Curr Mol Med  2022,22(4),325-335","journal-title":"Curr Mol Med"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"BSR20203565","DOI":"10.1042\/BSR20203565","volume":"41","author":"Xu L.","year":"2021","unstructured":"Xu L.; Zhang J.; Wang Y.; Zhang Z.; Wang F.; Tang X.; Uncovering the mechanism of Ge-Gen-Qin-Lian decoction for treating ulcerative colitis based on network pharmacology and molecular docking verification. Biosci Rep  2021,41(2),BSR20203565","journal-title":"Biosci Rep"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/j.jddst.2019.03.006","volume":"51","author":"Harwansh R.K.","year":"2019","unstructured":"Harwansh R.K.; Deshmukh R.; Rahman M.A.; Nanoemulsion: Promising nanocarrier system for delivery of herbal bioactives. J Drug Deliv Sci Technol  2019,51,224-233","journal-title":"J Drug Deliv Sci Technol"},{"key":"ref=85","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2174\/1567201819666220331094812","volume":"20","author":"Deshmukh R.","year":"2023","unstructured":"Deshmukh R.; Jain A.K.; Singh R.; Paul S.D.; Harwansh R.K.; Andrographis paniculata and andrographolide - a snapshot on recent advances in nano drug delivery systems against cancer. Curr Drug Deliv  2023,20,1-14","journal-title":"Curr Drug Deliv"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"e280422204154","DOI":"10.2174\/2215083808666220428092638","volume":"9","author":"Murti Y.","year":"2023","unstructured":"Murti Y.; Agrawal K.K.; Semwal B.C.; Gupta J.; Gupta R.; A review on novel herbal drug delivery system and its application. Curr Tradit Med  2023,9(2),e280422204154","journal-title":"Curr Tradit Med"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"255","DOI":"10.2174\/2210303110999200712185109","volume":"10","author":"Chaturvedi S.","year":"2020","unstructured":"Chaturvedi S.; Mishra R.; Insight into delivery approaches for biopharmaceutics classification system class II and IV drugs. Drug Deliv Lett  2020,10(4),255-277","journal-title":"Drug Deliv Lett"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"7291","DOI":"10.2147\/IJN.S146315","volume":"12","author":"Din F.","year":"2017","unstructured":"Din F.; Aman W.; Ullah I.; Qureshi O.S.; Mustapha O.; Shafique S.; Zeb A.; Effective use of nanocarriers as drug delivery systems for the treatment of selected tumors. Int J Nanomedicine  2017,12,7291-7309","journal-title":"Int J Nanomedicine"},{"key":"ref=89","doi-asserted-by":"crossref","first-page":"911","DOI":"10.2174\/1567201817666200717090623","volume":"17","author":"Deshmukh R.J.C.D.D.","year":"2020","unstructured":"Deshmukh R.J.C.D.D.; Bridging the gap of drug delivery in colon cancer: The role of chitosan and pectin based nanocarriers system. Curr Drug Deliv  2020,17(10),911-924","journal-title":"Curr Drug Deliv"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"e19147","DOI":"10.1590\/s2175-97902020000419147","volume":"57","author":"Deshmukh R.","year":"2021","unstructured":"Deshmukh R.; Harwansh R.K.; Rahman M.A.; Sodium alginate-guar gum and carbopol based methotrexate loaded mucoadhesive microparticles for colon delivery: An in vitroevaluation. Braz J Pharm Sci  2021,57,e19147","journal-title":"Braz J Pharm Sci"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.2147\/IJN.S289443","volume":"16","author":"Edis Z.","year":"2021","unstructured":"Edis Z.; Wang J.; Waqas M.K.; Ijaz M.; Ijaz M.; Nanocarriers-mediated drug delivery systems for anticancer agents: An overview and perspectives. Int J Nanomedicine  2021,16,1313-1330","journal-title":"Int J Nanomedicine"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.ijpharm.2015.05.008","volume":"490","author":"Li Q.","year":"2015","unstructured":"Li Q.; Zhai W.; Jiang Q.; Huang R.; Liu L.; Dai J.; Gong W.; Du S.; Wu Q.; Curcumin-piperine mixtures in self-microemulsifying drug delivery system for ulcerative colitis therapy. Int J Pharm  2015,490(1-2),22-31","journal-title":"Int J Pharm"},{"key":"ref=93","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.ijpharm.2009.10.016","volume":"385","author":"Das S.","year":"2010","unstructured":"Das S.; Ng K.Y.; Colon-specific delivery of resveratrol: Optimization of multi-particulate calcium-pectinate carrier. Int J Pharm  2010,385(1-2),20-28","journal-title":"Int J Pharm"},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.ijpharm.2016.10.002","volume":"515","author":"Wang Q.S.","year":"2016","unstructured":"Wang Q.S.; Wang G.F.; Zhou J.; Gao L.N.; Cui Y.L.; Colon targeted oral drug delivery system based on alginate-chitosan microspheres loaded with icariin in the treatment of ulcerative colitis. Int J Pharm  2016,515(1-2),176-185","journal-title":"Int J Pharm"},{"key":"ref=95","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.ijpharm.2011.10.045","volume":"422","author":"Rabi\u0161kov\u00e1 M.","year":"2012","unstructured":"Rabi\u0161kov\u00e1 M.; Bautzov\u00e1 T.; Gajdziok J.; Dvo\u0159\u00e1\u010dkov\u00e1 K.; Lamprecht A.; Pellequer Y.; Spilkov\u00e1 J.; Coated chitosan pellets containing rutin intended for the treatment of inflammatory bowel disease: in vitrocharacteristics and in vivo evaluation. Int J Pharm  2012,422(1-2),151-159","journal-title":"Int J Pharm"},{"key":"ref=96","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2014\/340701","volume":"2014","author":"Sareen R.","year":"2014","unstructured":"Sareen R.; Nath K.; Jain N.; Dhar K.L.; Curcumin loaded microsponges for colon targeting in inflammatory bowel disease: Fabrication, optimization, and in vitroand pharmacodynamic evaluation. BioMed Res Int  2014,2014,1-7","journal-title":"BioMed Res Int"},{"key":"ref=97","doi-asserted-by":"publisher","first-page":"211","DOI":"10.3109\/02652048.2014.995728","volume":"32","author":"Varshosaz J.","year":"2015","unstructured":"Varshosaz J.; Minaiyan M.; Khaleghi N.; Eudragit nanoparticles loaded with silybin: a detailed study of preparation, freeze-drying condition and in vitro\/in vivo evaluation. J Microencapsul  2015,32(3),211-223","journal-title":"J Microencapsul"},{"key":"ref=98","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1002\/jps.23828","volume":"103","author":"Gugulothu D.","year":"2014","unstructured":"Gugulothu D.; Kulkarni A.; Patravale V.; Dandekar P.; pH-sensitive nanoparticles of curcumin-celecoxib combination: Evaluating drug synergy in ulcerative colitis model. J Pharm Sci  2014,103(2),687-696","journal-title":"J Pharm Sci"},{"key":"ref=99","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1093\/ibd\/izy123","volume":"24","author":"Zhang M.","year":"2018","unstructured":"Zhang M.; Merlin D.; Nanoparticle-based oral drug delivery systems targeting the colon for treatment of ulcerative colitis. Inflamm Bowel Dis  2018,24(7),1401-1415","journal-title":"Inflamm Bowel Dis"},{"key":"ref=100","doi-asserted-by":"publisher","first-page":"644387","DOI":"10.3389\/fphar.2021.644387","volume":"12","author":"Zhao L.","year":"2021","unstructured":"Zhao L.; Du X.; Tian J.; Kang X.; Li Y.; Dai W.; Li D.; Zhang S.; Li C.; Berberine-loaded carboxylmethyl chitosan nanoparticles ameliorate DSS-induced colitis and remodel gut microbiota in mice. Front Pharmacol  2021,12,644387","journal-title":"Front Pharmacol"},{"key":"ref=101","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1021\/jf404621f","volume":"62","author":"Li Z.","year":"2014","unstructured":"Li Z.; Gu L.; Fabrication of self-assembled (-)-epigallocatechin gallate (EGCG) ovalbumin-dextran conjugate nanoparticles and their transport across monolayers of human intestinal epithelial Caco-2 cells. J Agric Food Chem  2014,62(6),1301-1309","journal-title":"J Agric Food Chem"},{"key":"ref=102","doi-asserted-by":"publisher","first-page":"669","DOI":"10.2147\/IJN.S154824","volume":"13","author":"Yen C.C.","year":"2018","unstructured":"Yen C.C.; Chen Y.C.; Wu M.T.; Wang C.C.; Wu Y.T.; Nanoemulsion as a strategy for improving the oral bioavailability and anti-inflammatory activity of andrographolide. Int J Nanomedicine  2018,13,669-680","journal-title":"Int J Nanomedicine"},{"key":"ref=103","doi-asserted-by":"publisher","first-page":"3610","DOI":"10.3390\/molecules27113610","volume":"27","author":"Peng J.","year":"2022","unstructured":"Peng J.; Cai Z.; Wang Q.; Zhou J.; Xu J.; Pan D.; Chen T.; Zhang G.; Tao L.; Chen Y.; Shen X.; Carboxymethyl chitosan modified oxymatrine liposomes for the alleviation of emphysema in mice via pulmonary administration. Molecules  2022,27(11),3610","journal-title":"Molecules"},{"key":"ref=104","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.colsurfb.2015.03.062","volume":"130","author":"Alvarado H.L.","year":"2015","unstructured":"Alvarado H.L.; Abrego G.; Souto E.B.; Gardu\u00f1o-Ramirez M.L.; Clares B.; Garc\u00eda M.L.; Calpena A.C.; Nanoemulsions for dermal controlled release of oleanolic and ursolic acids: in vitro, ex vivo and in vivo characterization. Colloids Surf B Biointerfaces  2015,130,40-47","journal-title":"Colloids Surf B Biointerfaces"},{"key":"ref=105","first-page":"223","author":"Kakran M.","year":"2011","unstructured":"Kakran M.; Sahoo N.; Li L.; Judeh Z.; Fabrication of quercetin nanoparticles by anti-solvent precipitation method for enhanced dissolution. Powder Technol  2011,223","journal-title":"Powder Technol"},{"key":"ref=106","doi-asserted-by":"publisher","first-page":"118555","DOI":"10.1016\/j.lfs.2020.118555","volume":"262","author":"Naserifar M.","year":"2020","unstructured":"Naserifar M.; Hosseinzadeh H.; Abnous K.; Mohammadi M.; Taghdisi S.M.; Ramezani M.; Alibolandi M.; Oral delivery of folate-targeted resveratrol-loaded nanoparticles for inflammatory bowel disease therapy in rats. Life Sci  2020,262,118555","journal-title":"Life Sci"},{"key":"ref=107","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1021\/acs.molpharmaceut.0c00048","volume":"18","author":"Pujara N.","year":"2021","unstructured":"Pujara N.; Wong K.Y.; Qu Z.; Wang R.; Moniruzzaman M.; Rewatkar P.; Kumeria T.; Ross B.P.; McGuckin M.; Popat A.; Oral delivery of \u03b2-lactoglobulin-nanosphere-encapsulated resveratrol alleviates inflammation in winnie mice with spontaneous ulcerative colitis. Mol Pharm  2021,18(2),627-640","journal-title":"Mol Pharm"},{"key":"ref=108","doi-asserted-by":"publisher","first-page":"120935","DOI":"10.1016\/j.ijpharm.2021.120935","volume":"606","author":"Diez-Echave P.","year":"2021","unstructured":"Diez-Echave P.; Ruiz-Malag\u00f3n A.J.; Molina-Tijeras J.A.; Hidalgo-Garc\u00eda L.; Vezza T.; Cenis-Cifuentes L.; Rodr\u00edguez-Sojo M.J.; Cenis J.L.; Rodr\u00edguez-Cabezas M.E.; Rodr\u00edguez-Nogales A.; G\u00e1lvez J.; Lozano-P\u00e9rez A.A.; Silk fibroin nanoparticles enhance quercetin immunomodulatory properties in DSS-induced mouse colitis. Int J Pharm  2021,606,120935","journal-title":"Int J Pharm"},{"key":"ref=109","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1211\/0022357011776469","volume":"53","author":"Jeong Y.I.","year":"2010","unstructured":"Jeong Y.I.; Yv\u0304 R.P.; Ohno T.; Yoshikawa Y.; Shibata N.; Kato S.; Takeuchi K.; Takada K.; Application of Eudragit P-4135F for the delivery of ellagic acid to the rat lower small intestine. J Pharm Pharmacol  2010,53(8),1079-1085","journal-title":"J Pharm Pharmacol"},{"key":"ref=110","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.2147\/IJN.S240449","volume":"15","author":"Liu C.S.","year":"2020","unstructured":"Liu C.S.; Chen L.; Hu Y.N.; Dai J.L.; Ma B.; Tang Q.F.; Tan X.M.; Self-microemulsifying drug delivery system for improved oral delivery and hypnotic efficacy of ferulic acid. Int J Nanomedicine  2020,15,2059-2070","journal-title":"Int J Nanomedicine"},{"key":"ref=111","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.ijpharm.2011.03.020","volume":"410","author":"Onoue S.","year":"2011","unstructured":"Onoue S.; Ochi M.; Yamada S.; Development of (\u2212)-epigallocatechin-3-gallate (EGCG)-loaded enteric microparticles with intestinal mucoadhesive property. Int J Pharm  2011,410(1-2),111-113","journal-title":"Int J Pharm"},{"key":"ref=112","doi-asserted-by":"publisher","first-page":"e01993","DOI":"10.1128\/mBio.01993-17","volume":"9","author":"Filippova E.V.","year":"2018","unstructured":"Filippova E.V.; Zemaitaitis B.; Aung T.; Wolfe A.J.; Anderson W.F.; Structural basis for DNA recognition by the two-component response regulator RcsB. MBio  2018,9(1),e01993-e17","journal-title":"MBio"},{"key":"ref=113","doi-asserted-by":"publisher","first-page":"3937","DOI":"10.2147\/IJN.S247406","volume":"15","author":"Deng J.","year":"2020","unstructured":"Deng J.; Wu Z.; Zhao Z.; Wu C.; Yuan M.; Su Z.; Wang Y.; Wang Z.; Berberine-loaded nanostructured lipid carriers enhance the treatment of ulcerative colitis. Int J Nanomedicine  2020,15,3937-3951","journal-title":"Int J Nanomedicine"}],"container-title":["Current Pharmaceutical Biotechnology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0113892010282432231222060355","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/225134\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0113892010282432231222060355","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,23]],"date-time":"2024-09-23T05:42:53Z","timestamp":1727070173000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/225134\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":113,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0113892010282432231222060355","relation":{},"ISSN":["1389-2010"],"issn-type":[{"value":"1389-2010","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2023-09-27","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-12-12","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-12-15","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-07-11","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}